Navigation Links
Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the 'CL Seal of Approval' a Worthless, Paid-For Advertising Gimmick
Date:1/24/2008

s ratings and sells advertising to the parent companies of the products they are currently testing or may test in the future is NOT independent, and we're not the first to recognize this farce," suggests DiGeorgia.

DiGeorgia points to the Council for Responsible Nutrition (CRN), who, in 2005, asked the Federal Trade Commission to investigate ConsumerLab.com for deceptive business practices as one such example.

CRN pointed out that in the very letter ConsumerLab.com sent to the FTC in an attempt to defend its business, ConsumerLab.com "admits to the very business practices about which we are complaining, but in a manner so oblique that only those of us who fully understand the ConsumerLab business plan will comprehend the admission," reports DiGeorgia.

Additionally, in August 2006, Marc Ullman, a New York City attorney and who also manages FYI Newsletter, which highlights legal and regulatory issues concerning the Natural Product Industry, wrote:

"Since its inception, ConsumerLab.com has succeeded in presenting itself

to the mainstream media as an impartial watchdog of the dietary

supplement industry. It has managed to accomplish this despite the

fundamentally flawed nature of its basic business plan - ConsumerLab.com

solicits money from both the industry it purports to police and the

consumers it purports to protect. (Not to mention that it is not a lab

either.)"

"ConsumerLab.com has now taken the conflict of interest one step further, and we believe has completely exposed the absurdity of its claim to independence," says Michael London, general manager of Renaissance Health Publishing, LLC.

"They're currently allowing a competitor of ours to advertise on the ConsumerLab.com website. And by allowing a link back to the competitor's Web site ConsumerLab.com is allowing this competitor-who we have been in litigation with for more than a year-to use the misleading and out-of-dat
'/>"/>

SOURCE Renaissance Health Publishing, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Renaissance Health Publishing, LLC Asks Key Credibility Questions of ConsumerLab.com
2. ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Avamere Health Systems Announces New President of Signature Home Health
5. Controlling health destiny
6. The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America
7. Healthcare Workers Skeptical of Planning Process for St. Lukes
8. From Research to Practice: Healthfitness, Eastman Chemical Company Case Study Demonstrates Real-World Health Gains and Productivity Savings
9. AMA on the State of Health Care in Advance of the Presidential State of the Union Address
10. Boston Research Summit gathers 100 health care leaders on decision making
11. Accuro Healthcare Solutions, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... Dennis Thompson HealthDay Reporter ... experimental Ebola drug previously given to two American aid workers ... virus in laboratory tests, researchers report. The drug, ZMapp, ... if they didn,t get the medication until five days after ... Ebola who were days or even hours away from death, ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Top10BestSEOHosting.com ... evaluating many web host suppliers carefully, Top10BestSEOHosting.com is ... are the best web hosting suppliers in 2014. ... old clients with a top-of-the-line shared hosting plan. ... an easy-to-use platform that is affordable, accessible and ...
(Date:9/1/2014)... 01, 2014 Pastor Thompson is an ordained ... Eagle Village. He is a licensed minister through the Church ... past twenty years in New Mexico, Colorado and North Dakota. ... marriage this year. He also has two beautiful daughters, ... in Pastoral Ministry from Nazarene Bible College, in Colorado Springs ...
Breaking Medicine News(10 mins):Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2
... cosmetics shows it may have prevented, treated eye infections ... eye makeup worn thousands of years ago by Queen ... used to enhance beauty alone: New research suggests that ... eye disease. , Some ancient Egyptians thought their ...
... ... its’ addition of three exceptional leaders to their management team. Anne Reynolds and ... aboard as the Client Accounting Manager. , ... Columbus, OH (PRWEB) January 22, 2010 -- ADVOCATE, the premier ...
... ... identified brain networks damaged in Parkinson’s disease have new evidence that these systems become ... appear to respond in a last ditch attempt to rescue the brain. , ... Manhasset, NY (Vocus) January ...
... Jan. 22 Healthcare Trust of America, Inc. ... execution of a purchase and sale agreement to acquire an ... Georgia for approximately $19,550,000 . The closing of ... The medical office portfolio is 94% leased and is on ...
... Pa. , Jan. 22 ReSearch Pharmaceutical Services, Inc. ... and Steven Bell , Chief Financial Officer, will present at ... 25–27, 2010 in New York City .   , The ... 11:45 am, EST .  Mr. Perlman will also participate in ...
... find , FRIDAY, Jan. 22 (HealthDay News) -- Environment ... children,s reading skills, a new study finds. , "We ... learning, but children who come into school with poor ... author Stephen Petrill, a professor of human development and ...
Cached Medicine News:Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 2Health News:Explosive Growth Fuels Expansion of ADVOCATE's Management Team 3Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 2Health News:Brain Abnormalities in Parkinson's Patients Develop Before Symptoms Occur, According to Feinstein Scientists 3Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire 80,562 Square Foot Medical Office Portfolio Located in Atlanta, Georgia 3Health News:ReSearch Pharmaceutical Services, Inc. to Present at Jefferies 2010 Global Healthcare Conference 2Health News:Environment Crucial to Boosting Child's Reading Skills 2
(Date:8/29/2014)... Medina Medical announced today that Mr. Engelson ... Board of Directors on August 18, 2014. Mr. Engelson ... experience, including over a decade of direct experience in ... Partner of the medical device incubator The Foundry, after ... start-ups. Mr. Engelson previously served as the Chief Financial ...
(Date:8/29/2014)... Research and Markets has announced the addition ... Pipeline Insight 2014" report to their offering. ... eradicate the prevalence of cancer have achieved limited success ... specificity, safety and large number of side effects, which ... It has been discovered that peptides can be used ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
... 3 ,GlaxoSmithKline (NYSE: GSK ; LSE) today ... has granted Priority Review for PROMACTA(R),(eltrombopag) for the ... (ITP). PROMACTA is an investigational,once-daily oral treatment that ... to generate platelets, which are critical in minimizing ...
... Shows Statistically Significant Pain Relief with the 2.5 ... and 5 mg Doses ... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today positive top-line,results ... (Staccato(R),loxapine) in patients with migraine headache. Migraine is a debilitating,yet ...
Cached Medicine Technology:FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 2FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 3FDA Grants Priority Review for PROMACTA(R) (eltrombopag) 4Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 2Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 3Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 4Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 5Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 6Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 7Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache 8
Porous foundation 480 series....
Cemented foundation 460 series....
Porous foundation 440 series....
The AcuMatch M-Series modular femoral stem is a unique, innovative three-piece modular stem designed to address even the most complicated of clinical indications....
Medicine Products: